GlassScriptPhysician profile
Amber N Tilley
NPI 1790058709
$4,469.54
in general payments reported to CMS, 2019-2025
39 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $847 · 2022: $713 · 2023: $831 · 2024: $997 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,909.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.01 | 2021-2025 | |
| Pfizer INC. | $516.81 | 2021-2025 | |
| Glaxosmithkline, LLC. | $459.35 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $350.49 | 2023-2025 | Breztri, Airsupra, Fasenra |
| Novo Nordisk INC | $340.76 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $244.80 | 2021-2025 | Jardiance, Kisunla, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $185.61 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $180.71 | 2021-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.30 | 2021-2024 | Xifaxan, Trulance |
| Lundbeck LLC | $133.28 | 2023-2025 | Rexulti |
| Corcept Therapeutics | $124.63 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.67 | 2022-2025 | Caplyta |
| Corium, LLC | $104.77 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $62.64 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $60.32 | 2023-2025 | Austedo Xr, Austedo Xr |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Tilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.